Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04532346 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Re-verified, no change to tracked fieldsv11
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2024 to Sep 1, 2024
    • Site details revised
    v10
  3. Notable Start date: Mar 2024 to Sep 2024
    • Primary completion date: Apr 2026 to Oct 2026
    • Study completion date: Oct 2026 to Apr 2027
    v9
  4. Notable Start date: Sep 2023 to Mar 2024
    • Primary completion date: Oct 2025 to Apr 2026
    • Study completion date: Apr 2026 to Oct 2026
    v8
  5. Notable Start date: Mar 2023 to Sep 2023
    • Primary completion date: Apr 2025 to Oct 2025
    • Study completion date: Oct 2025 to Apr 2026
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Notable Primary completion date: Sep 2024 to Apr 2025
    • Start date: Aug 2022 to Mar 2023
    • Study completion date: Mar 2025 to Oct 2025
    v6
  2. Notable Primary completion date: Jan 2024 to Sep 2024
    • Start date: Feb 2022 to Aug 2022
    • Study completion date: Jul 2024 to Mar 2025
    v5
  3. Notable Start date: Nov 2021 to Feb 2022
    • Primary completion date: Oct 2023 to Jan 2024
    • Study completion date: Apr 2024 to Jul 2024
    v4
  4. Notable Primary completion date: Mar 2023 to Oct 2023
    • Start date: Apr 2021 to Nov 2021
    • Study completion date: Sep 2023 to Apr 2024
    v3
  5. Notable Start date: Oct 2020 to Apr 2021
    • Primary completion date: Sep 2022 to Mar 2023
    • Study completion date: Mar 2023 to Sep 2023
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this proposed study is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) in children's interstitial lung diseases(chILD) with genetic causes. This study is a randomized controlled clinical trial.
Trial Details
NCT Number NCT04532346
Lead Sponsor Children's Hospital of Fudan University
Conditions
(from sponsor)
Interstitial Lung Disease, Surfactant Dysfunction
Related terms Lung Diseases, Interstitial, Surfactant Dysfunction
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov